GlassScriptPhysician profile
Aya Ahram
NPI 1710448691
$4,101.98
in general payments reported to CMS, 2019-2025
20 companies · $1,224 in 2025
The $1,224 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.25 · 2020: $40.85 · 2021: $159 · 2022: $1,128 · 2023: $757 · 2024: $770 · 2025: $1,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,651 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,650.52 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,344.32 | 2020-2025 | Skyrizi, Rinvoq |
| Arcutis Biotherapeutics, INC. | $526.44 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $366.25 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $332.33 | 2024-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $299.36 | 2025 | Tremfya |
| Epi Health, LLC | $244.64 | 2020-2022 | |
| Leo Pharma INC. | $214.31 | 2024-2025 | Adbry |
| Amgen INC. | $156.18 | 2022-2024 | Otezla |
| Incyte Corporation | $153.58 | 2023-2025 | Opzelura |
| Genzyme Corporation | $121.82 | 2022 | |
| Revance Therapeutics, INC. | $88.97 | 2024-2025 | Daxxify |
| Sun Pharmaceutical Industries INC. | $54.15 | 2025 | Winlevi |
| Novartis Pharmaceuticals Corporation | $41.33 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.87 | 2023 | Spevigo |
| Journey Medical Corporation | $27.41 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $23.25 | 2019 | |
| Galderma Laboratories, L.P. | $22.43 | 2025 | |
| Ucb, INC. | $18.18 | 2023 | Cimzia |
| Nabriva Therapeutics, Plc | $14.11 | 2022 | |
| Dermavant Sciences, INC. | $14.05 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aya Ahram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.